Literature DB >> 27855847

p15 Expression Differentiates Nevus from Melanoma.

Laura A Taylor1, Conor O'Day2, Tzvete Dentchev2, Kyle Hood3, Emily Y Chu4, Todd W Ridky2, John T Seykora5.   

Abstract

Most melanomas are driven by BRAF(V600E)-activating mutations, while nevi harboring the same mutations have growth arrest. Although decreased p16 expression has been associated with melanoma formation, in recent work, p15 represented a primary effector of oncogene-induced senescence in nevomelanocytes that was diminished in melanomas. This study determined whether decreased p15 levels represent a general biomarker for the transition from nevus to melanoma. We performed p15 and p16 IHC analyses on a random series of nevi and melanomas. Staining was evaluated and graded for percentage and intensity to determine the H score. For real-time quantitative RT-PCR analysis of p15, RNA was extracted from FFPE sections from 14 nevus and melanoma samples via macrodissection. A two-sided t-test was used to evaluate between-group differences in mean H scores and qΔCt values. p15 Expression was significantly increased in melanocytic nevi compared with melanomas (mean H scores, 254.8 versus 132.3; P < 0.001). On p15 staining, the H score differential was greater than that with p16 staining [122.5 (P < 0.001) and 64.8 (P = 0.055), respectively]. Real-time quantitative RT-PCR analysis revealed a lower mean qΔCt value in melanomas, consistent with lower p15 expression (P = 0.018). Together, these data support the hypothesis that decreased p15 expression is a robust biomarker for distinguishing nevus from melanoma.
Copyright © 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27855847      PMCID: PMC5225287          DOI: 10.1016/j.ajpath.2016.08.009

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

Review 1.  Guilty as charged: B-RAF is a human oncogene.

Authors:  Mathew J Garnett; Richard Marais
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

Review 2.  B-RAF and melanocytic neoplasia.

Authors:  Melissa Gill; Julide Tok Celebi
Journal:  J Am Acad Dermatol       Date:  2005-07       Impact factor: 11.527

3.  Do all melanomas come from "moles"? A study of the histological association between melanocytic naevi and melanoma.

Authors:  R Marks; A P Dorevitch; G Mason
Journal:  Australas J Dermatol       Date:  1990       Impact factor: 2.875

4.  Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.

Authors:  Betsy N Perry; Cynthia Cohen; Baskaran Govindarajan; George Cotsonis; Jack L Arbiser
Journal:  Arch Dermatol       Date:  2006-08

Review 5.  Is there more than one road to melanoma?

Authors:  Jason K Rivers
Journal:  Lancet       Date:  2004-02-28       Impact factor: 79.321

6.  Cutaneous melanomas associated with nevi.

Authors:  Caroline Bevona; William Goggins; Timothy Quinn; Julie Fullerton; Hensin Tsao
Journal:  Arch Dermatol       Date:  2003-12

7.  High frequency of BRAF mutations in nevi.

Authors:  Pamela M Pollock; Ursula L Harper; Katherine S Hansen; Laura M Yudt; Mitchell Stark; Christiane M Robbins; Tracy Y Moses; Galen Hostetter; Urs Wagner; John Kakareka; Ghadi Salem; Tom Pohida; Peter Heenan; Paul Duray; Olli Kallioniemi; Nicholas K Hayward; Jeffrey M Trent; Paul S Meltzer
Journal:  Nat Genet       Date:  2002-11-25       Impact factor: 38.330

8.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

9.  Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?

Authors:  T M Skender-Kalnenas; D R English; P J Heenan
Journal:  J Am Acad Dermatol       Date:  1995-12       Impact factor: 11.527

10.  The Genetic Evolution of Melanoma from Precursor Lesions.

Authors:  A Hunter Shain; Iwei Yeh; Ivanka Kovalyshyn; Aravindhan Sriharan; Eric Talevich; Alexander Gagnon; Reinhard Dummer; Jeffrey North; Laura Pincus; Beth Ruben; William Rickaby; Corrado D'Arrigo; Alistair Robson; Boris C Bastian
Journal:  N Engl J Med       Date:  2015-11-12       Impact factor: 91.245

View more
  4 in total

1.  Expression of p15 in a spectrum of spitzoid melanocytic neoplasms.

Authors:  Sophia A Ma; Conor P O'Day; Tzvete Dentchev; Junko Takeshita; Todd W Ridky; John T Seykora; Emily Y Chu
Journal:  J Cutan Pathol       Date:  2019-02-14       Impact factor: 1.587

2.  Oncogenic BRAF mutations and p16 expression in melanocytic nevi and melanoma in the Polish population.

Authors:  Małgorzata Mackiewicz-Wysocka; Patrycja Czerwińska; Violetta Filas; Elżbieta Bogajewska; Agata Kubicka; Anna Przybyła; Ewelina Dondajewska; Tomasz Kolenda; Andrzej Marszałek; Andrzej Mackiewicz
Journal:  Postepy Dermatol Alergol       Date:  2017-10-31       Impact factor: 1.837

3.  Treatment of melanoma with selected inhibitors of signaling kinases effectively reduces proliferation and induces expression of cell cycle inhibitors.

Authors:  Dorota Ciołczyk-Wierzbicka; Dorota Gil; Piotr Laidler
Journal:  Med Oncol       Date:  2017-12-06       Impact factor: 3.064

4.  Identification, Validation, and Functional Annotations of Genome-Wide Profile Variation between Melanocytic Nevus and Malignant Melanoma.

Authors:  Wei Han; Wen-Hao Xu; Jian-Xiong Wang; Jia-Min Hou; Hai-Liang Zhang; Xiao-Yu Zhao; Guo-Liang Shen
Journal:  Biomed Res Int       Date:  2020-08-31       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.